Coherus gains on PK/PD readout for Neulasta biosimilar

Coherus BioSciences Inc. (NASDAQ:CHRS) gained $4.71 (27%) to $21.93 on Monday after it said CHS-1701

Read the full 154 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE